<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00342628</url>
  </required_header>
  <id_info>
    <org_study_id>999999050</org_study_id>
    <secondary_id>OH99-CH-N050</secondary_id>
    <nct_id>NCT00342628</nct_id>
  </id_info>
  <brief_title>Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants</brief_title>
  <official_title>Evaluation of the Safety, Immunogenicity and Compatibility With DTP of an Investigational Vi-rEPA Conjugate Vaccine for Typhoid Fever When Administered to Infants in Vietnam Concurrently With DTP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, immunogenicity, and compatibility of our
      Vi-rEPA conjugate administered to infants with their routine vaccinations.

      We propose to recruit 300 full term healthy newborns in Vietnam and randomly divide them to
      receive Vi-rEPA plus DTP, Hib-TT (not yet used in Vietnam) plus DTP, or DTP alone. Consent is
      obtained following interviews of mothers during prenatal visits, or after delivery. All
      vaccines will be administered at 2, 4, and 6 months. A booster of Vi-rEPA or Hib-TT conjugate
      will be administered at 12 months of age and reactions monitored at 6, 24 and 48 hours after
      each injection. Maternal and cord blood samples are collected during labor and at delivery.
      Blood will be taken at 7, and 12 months of age from all study infants and at 13 months from
      infants injected with Vi-rEPA or with Hib-TT at 12 months. The blood samples will be assayed
      for Vi, Hib, diphtheria, tetanus and pertussis antibodies.

      The levels of serum IgG anti-Vi elicited by Vi-rEPA administered to infants by the above
      schedule will be compared to those elicited by this vaccine in 2 to 5 year-olds in the
      efficacy trial conducted in Dong Thap Province, Vietnam.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Typhoid fever remains common, serious, and difficult-to-treat throughout the world including
      Vietnam. Limitations of the three licensed typhoid vaccines have prevented their use for
      routine vaccination of infants. The most recent, Vi polysaccharide typhoid vaccine is useful
      only in individuals greater than or equal to 5 years of age because of its age-related and
      T-cell independent properties. The immunogenicity of Vi in individuals less than 5 years-old
      has been improved by binding it to a protein. In 2 to 4-year-olds, 2 injections of the Vi
      conjugate induced higher levels of serum IgG anti-Vi than Vi in 5 to 14-year-olds.

      A double-blind, placebo controlled and randomized efficacy study in 2 -to-5 years old
      children in Vietnam showed an over-all efficacy after 27 months of active surveillance
      followed by 19 months of passive surveillance of 89%. Subsequently a dosage study in the same
      age group showed the highest antibody levels were induced by the 25 mcg dose.

      Now we wish to evaluate the safety, immunogenicity, and compatibility of our Vi-rEPA
      conjugate administered to infants with their routine vaccinations.

      We propose to recruit 300 full term healthy newborns in Vietnam and randomly divide them to
      receive Vi-rEPA plus DTP (Group A), Hib-TT (not yet used in Vietnam) plus DTP (Group B), or
      DTP alone (Group C). Maternal and cord blood are taken routinely on all deliveries in
      Vietnam; these sera will be retrieved for storage when consent is obtained following
      interviews of mothers during prenatal visits, or after delivery. All vaccines will be
      administered at 2, 4, and 6 months. A booster of Vi-rEPA or Hib-TT conjugate will be
      administered at 12 months of age and reactions monitored at 6, 24 and 48 hours after each
      injection. Blood will be taken at 7, and 12 months of age from all study infants and at 13
      months from infants injected with Vi-rEPA or with Hib-TT at 12 months. The blood samples will
      be assayed for Vi, Hib, diphtheria, tetanus and pertussis antibodies.

      The levels of serum IgG anti-Vi elicited by Vi-rEPA administered to infants by the above
      schedule will be compared to those elicited by this vaccine in 2 to 5 year-olds in the
      efficacy trial conducted in Dong Thap.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Infants With Adverse Reactions After Vaccination</measure>
    <time_frame>at 2, 4, 6 and 12 months</time_frame>
    <description>Number of infants with Fever&gt;=38.0 C, Induration&gt;=2.5cm at DTP site, Induration&gt;=2.5cm,Vi-rEPA/Hib-TT site, Erythema&gt;=2.5cm, at DTP site, Erythema&gt;=2.5cm, Vi-rEPA/Hib-TT site, Inconsolable crying&lt;4hr, Inconsolable crying&gt;=4hr per injection with Vi conjugate vaccine given in conjunction with DTP in infants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgG Anti-Vi Levels</measure>
    <time_frame>cord sera, infants' sera at 7, 12 and 13 months</time_frame>
    <description>IgG anti-Vi was measured by ELISA and expressed as ELISA units (EU)in all sera.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Responses to Tetanus Toxoid, Diphtheria Toxoid, and Pertussis Toxin</measure>
    <time_frame>Cord sera, and infants' sera at 7, 12 and 13 months of age</time_frame>
    <description>IgG anti-diphtheria toxoid (DT), -tetanus toxoid (TT) and -pertussis toxin (PT) were measured by ELISA in sera of 30 randomly chosen infants per group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Responses to Hib CP</measure>
    <time_frame>Cord sera and infant sera at 7, 12, and 13 months</time_frame>
    <description>IgG anti-Hib CP was measured by ELISA in sera of 30 randomly chosen infants per group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>Vi-rEPA plus DTP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vi-rEPA and DTP at 2, 4, 6 months, and Vi-rEPA at 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hib-TT plus DTP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hib-TT and DTP at 2,4 and 6 months, Hib-TT at 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DTP at 2,4 and 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi-rEPA conjugate vaccine for typhoid fever</intervention_name>
    <description>Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.</description>
    <arm_group_label>Vi-rEPA plus DTP</arm_group_label>
    <other_name>Vi conjugate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib-TT</intervention_name>
    <description>Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid</description>
    <arm_group_label>Hib-TT plus DTP</arm_group_label>
    <other_name>Hib conjugate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTP</intervention_name>
    <description>DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization</description>
    <arm_group_label>Vi-rEPA plus DTP</arm_group_label>
    <arm_group_label>Hib-TT plus DTP</arm_group_label>
    <arm_group_label>EPI</arm_group_label>
    <other_name>EPI vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy full-term newborns.

          -  Birth weights of &gt;=2500 grams.

        Exclusion criteria:

          -  Newborns without maternal and cord blood samples

          -  Newborns born to mothers with serious medical problems.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng-Ying (Kimi) Lin, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>PDMI, NICHD, NIH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thanh Thuy District Health Center</name>
      <address>
        <city>Viet Tri</city>
        <state>Phu Tho Province</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, Schulz D, Armand J, Bryla DA, Trollfors B, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med. 1987 Oct 29;317(18):1101-4.</citation>
    <PMID>3657877</PMID>
  </reference>
  <reference>
    <citation>Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. Clin Infect Dis. 2010 Jan 15;50(2):241-6. doi: 10.1086/649541. Review.</citation>
    <PMID>20014951</PMID>
  </reference>
  <reference>
    <citation>Gilman RH, Terminel M, Levine MM, Hernandez-Mendoza P, Hornick RB. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet. 1975 May 31;1(7918):1211-3.</citation>
    <PMID>48834</PMID>
  </reference>
  <reference>
    <citation>Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D, Cadoz M, Armand J. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 1987 Nov 21;2(8569):1165-9.</citation>
    <PMID>2890805</PMID>
  </reference>
  <reference>
    <citation>Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun. 1999 Nov;67(11):5806-10.</citation>
    <PMID>10531232</PMID>
  </reference>
  <reference>
    <citation>Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, Chu C, Schiloach J, Robbins JB, Schneerson R, Szu SC. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med. 2003 Oct 2;349(14):1390-1.</citation>
    <PMID>14523155</PMID>
  </reference>
  <reference>
    <citation>Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine. 1999 Oct 1;17 Suppl 2:S22-7.</citation>
    <PMID>10506405</PMID>
  </reference>
  <reference>
    <citation>Lin FY, Vo AH, Phan VB, Nguyen TT, Bryla D, Tran CT, Ha BK, Dang DT, Robbins JB. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg. 2000 May;62(5):644-8.</citation>
    <PMID>11289678</PMID>
  </reference>
  <reference>
    <citation>Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001 Apr 26;344(17):1263-9.</citation>
    <PMID>11320385</PMID>
  </reference>
  <reference>
    <citation>Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, Bhutta ZA, Canh DG, Ali M, Shin S, Wain J, Page AL, Albert MJ, Farrar J, Abu-Elyazeed R, Pang T, Galindo CM, von Seidlein L, Clemens JD; Domi Typhoid Study Group. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008 Apr;86(4):260-8. Erratum in: Bull World Health Organ. 2015 Apr 1;93(4):284. Bull World Health Organ. 2015 Jun 1;93(6):440.</citation>
    <PMID>18438514</PMID>
  </reference>
  <reference>
    <citation>Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, Rao M, Naficy A, Clemens JD, Bhan MK. Typhoid fever in children aged less than 5 years. Lancet. 1999 Aug 28;354(9180):734-7.</citation>
    <PMID>10475185</PMID>
  </reference>
  <reference>
    <citation>Szu SC, Stone AL, Robbins JD, Schneerson R, Robbins JB. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med. 1987 Nov 1;166(5):1510-24.</citation>
    <PMID>3681191</PMID>
  </reference>
  <reference>
    <citation>Taylor DN, Levine MM, Kuppens L, Ivanoff B. Why are typhoid vaccines not recommended for epidemic typhoid fever? J Infect Dis. 1999 Dec;180(6):2089-90.</citation>
    <PMID>10558978</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2006</study_first_posted>
  <results_first_submitted>March 30, 2012</results_first_submitted>
  <results_first_submitted_qc>May 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2012</results_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody</keyword>
  <keyword>Reactions</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Conjugate Vaccine</keyword>
  <keyword>Typhoid Fever</keyword>
  <keyword>Trial</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Comparability</keyword>
  <keyword>DTP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Informed consent was obtained from expectant women during prenatal visits in Thanh Thuy District, Phu-Tho Province, Vietnam. Mothers and newborns were enrolled during labor at commune/district health centers from July 26, 2006 to March 8, 2007. Only fullterm newborns with birth weights of &gt;=2500 grams were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vi-rEPA Plus DTP</title>
          <description>Vi-rEPA plus DTP at 2, 4, 6 and Vi-rEPA at 12 months of age</description>
        </group>
        <group group_id="P2">
          <title>Hib-TT Plus DTP</title>
          <description>Hib-TT plus DTP at 2,4,6 and Hib-TT at 12 months of age</description>
        </group>
        <group group_id="P3">
          <title>DTP Vaccines</title>
          <description>DTP at 2, 4, and 6 months of age</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80">84 completed 4 injections, 4 were lost-to-followup after the 4th injection</participants>
                <participants group_id="P2" count="80">83 completed 4 injections, 3 were lost-to-followup after 4th injection</participants>
                <participants group_id="P3" count="81">97 completed 3 injections of DTP alone, 16 were lost-to-followup for blood drawing at 12 months.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>moved residence</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vi-rEPA Plus DTP</title>
          <description>Vi-rEPA plus DTP at 2, 4, 6 and Vi-rEPA at 12 months of age</description>
        </group>
        <group group_id="B2">
          <title>Hib-TT Plus DTP</title>
          <description>Hib-TT plus DTP at 2,4,6 and Hib-TT at 12 months of age</description>
        </group>
        <group group_id="B3">
          <title>DTP Vaccines</title>
          <description>DTP at 2, 4, and 6 months of age</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="301"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Study participants are infants recruited at birth, injected with experimental and comparison vaccine at 2, 4, 6 and 12 months of age.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age at 1st injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" lower_limit="61" upper_limit="92"/>
                    <measurement group_id="B2" value="76" lower_limit="61" upper_limit="92"/>
                    <measurement group_id="B3" value="76" lower_limit="61" upper_limit="92"/>
                    <measurement group_id="B4" value="77" lower_limit="61" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age at 2nd injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137" lower_limit="121" upper_limit="151"/>
                    <measurement group_id="B2" value="137" lower_limit="120" upper_limit="154"/>
                    <measurement group_id="B3" value="137" lower_limit="121" upper_limit="151"/>
                    <measurement group_id="B4" value="137" lower_limit="120" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age at 3rd injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197" lower_limit="181" upper_limit="212"/>
                    <measurement group_id="B2" value="198" lower_limit="182" upper_limit="211"/>
                    <measurement group_id="B3" value="197" lower_limit="181" upper_limit="211"/>
                    <measurement group_id="B4" value="197" lower_limit="181" upper_limit="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age at 4th injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="382" lower_limit="365" upper_limit="420"/>
                    <measurement group_id="B2" value="381" lower_limit="365" upper_limit="406"/>
                    <measurement group_id="B3" value="NA">No injection given</measurement>
                    <measurement group_id="B4" value="382" lower_limit="365" upper_limit="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Infants With Adverse Reactions After Vaccination</title>
        <description>Number of infants with Fever&gt;=38.0 C, Induration&gt;=2.5cm at DTP site, Induration&gt;=2.5cm,Vi-rEPA/Hib-TT site, Erythema&gt;=2.5cm, at DTP site, Erythema&gt;=2.5cm, Vi-rEPA/Hib-TT site, Inconsolable crying&lt;4hr, Inconsolable crying&gt;=4hr per injection with Vi conjugate vaccine given in conjunction with DTP in infants.</description>
        <time_frame>at 2, 4, 6 and 12 months</time_frame>
        <population>The number of infants injected in each group for each injection was used to determine the rate of adverse reactions.</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-rEPA Plus DTP</title>
            <description>Vi-rEPA plus DTP at 2, 4, 6 and Vi-rEPA at 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>Hib-TT Plus DTP</title>
            <description>Hib-TT plus DTP at 2,4,6 and Hib-TT at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>DTP Vaccines</title>
            <description>DTP at 2, 4, and 6 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Adverse Reactions After Vaccination</title>
          <description>Number of infants with Fever&gt;=38.0 C, Induration&gt;=2.5cm at DTP site, Induration&gt;=2.5cm,Vi-rEPA/Hib-TT site, Erythema&gt;=2.5cm, at DTP site, Erythema&gt;=2.5cm, Vi-rEPA/Hib-TT site, Inconsolable crying&lt;4hr, Inconsolable crying&gt;=4hr per injection with Vi conjugate vaccine given in conjunction with DTP in infants.</description>
          <population>The number of infants injected in each group for each injection was used to determine the rate of adverse reactions.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever&gt;=38.0 C 1st inj</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever&gt;=38.0 C 2nd inj</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever&gt;=38.0 C 3rd inj</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever&gt;=38.0 C 4th inj</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no injection for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration&gt;=2.5cm, at DTP site, Inj 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration&gt;=2.5cm, at DTP site, Inj 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration&gt;=2.5cm, at DTP site, Inj 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration&gt;=2.5cm, at DTP site, Inj 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No injection for this group</measurement>
                    <measurement group_id="O2" value="NA">no injection for this group</measurement>
                    <measurement group_id="O3" value="NA">no injection for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration&gt;=2.5cm,Vi-rEPA/Hib-TT site, Inj 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no Vi-rEPA/Hib-TT site for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration&gt;=2.5cm,Vi-rEPA/Hib-TT site, Inj 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no Vi-rEPA/Hib-TT site for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration&gt;=2.5cm,Vi-rEPA/Hib-TT site, Inj 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no Vi-rEPA/Hib-TT site for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration&gt;=2.5cm,Vi-rEPA/Hib-TT site, Inj 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no Vi-rEPA/Hib-TT site for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema&gt;=2.5cm, at DTP site, Inj 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema&gt;=2.5cm, at DTP site, Inj 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema&gt;=2.5cm, at DTP site, Inj 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema&gt;=2.5cm, at DTP site, Inj 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No injection for this group</measurement>
                    <measurement group_id="O2" value="NA">no injection for this group</measurement>
                    <measurement group_id="O3" value="NA">no injection for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema&gt;=2.5cm, Vi-rEPA/Hib-TT site, Inj 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no Vi-rEPA/Hib-TT site for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema&gt;=2.5cm, Vi-rEPA/Hib-TT site, Inj 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no Vi-rEPA/Hib-TT site for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema&gt;=2.5cm, Vi-rEPA/Hib-TT site, Inj 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no Vi-rEPA/Hib-TT site for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema&gt;=2.5cm, Vi-rEPA/Hib-TT site, Inj 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no Vi-rEPA/Hib-TT site for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconsolable crying&lt;4hr, inj 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconsolable crying&lt;4hr, inj 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconsolable crying&lt;4hr, inj 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconsolable crying&lt;4hr, inj 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no injection for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconsolable crying&gt;=4hr, inj 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconsolable crying&gt;=4hr, inj 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconsolable crying&gt;=4hr, inj 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconsolable crying&gt;=4hr, inj 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">no injection for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IgG Anti-Vi Levels</title>
        <description>IgG anti-Vi was measured by ELISA and expressed as ELISA units (EU)in all sera.</description>
        <time_frame>cord sera, infants' sera at 7, 12 and 13 months</time_frame>
        <population>Only participants with available cord sera are included in the analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-rEPA Plus DTP</title>
            <description>Vi-rEPA plus DTP at 2, 4, 6 and Vi-rEPA at 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>Hib-TT Plus DTP</title>
            <description>Hib-TT plus DTP at 2,4,6 and Hib-TT at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>DTP Vaccines</title>
            <description>DTP at 2, 4, and 6 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>IgG Anti-Vi Levels</title>
          <description>IgG anti-Vi was measured by ELISA and expressed as ELISA units (EU)in all sera.</description>
          <population>Only participants with available cord sera are included in the analyses</population>
          <units>ELISA units</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgG anti-Vi (cord sera)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.30" upper_limit="1.46"/>
                    <measurement group_id="O2" value="0.55" lower_limit="0.26" upper_limit="1.02"/>
                    <measurement group_id="O3" value="0.52" lower_limit="0.20" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG anti-Vi at 7 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.42" lower_limit="7.33" upper_limit="47.25"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.10" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.05" lower_limit="0.02" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG anti-Vi at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" lower_limit="2.20" upper_limit="12.71"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.11" upper_limit="0.27"/>
                    <measurement group_id="O3" value="0.04" lower_limit="0.02" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG anti-Vi at 13 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.07" lower_limit="22.33" upper_limit="133.61"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.11" upper_limit="0.27"/>
                    <measurement group_id="O3" value="NA">No serum samples were collected for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Responses to Tetanus Toxoid, Diphtheria Toxoid, and Pertussis Toxin</title>
        <description>IgG anti-diphtheria toxoid (DT), -tetanus toxoid (TT) and -pertussis toxin (PT) were measured by ELISA in sera of 30 randomly chosen infants per group.</description>
        <time_frame>Cord sera, and infants' sera at 7, 12 and 13 months of age</time_frame>
        <population>Randomly chosen 30 participants in each group. Four in Comparison group 2 were excluded from analyses due to classification error.</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-rEPA Plus DTP</title>
            <description>Vi-rEPA plus DTP at 2, 4, 6 and Vi-rEPA at 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>Hib-TT Plus DTP</title>
            <description>Hib-TT plus DTP at 2,4,6 and Hib-TT at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>DTP Vaccines</title>
            <description>DTP at 2, 4, and 6 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Responses to Tetanus Toxoid, Diphtheria Toxoid, and Pertussis Toxin</title>
          <description>IgG anti-diphtheria toxoid (DT), -tetanus toxoid (TT) and -pertussis toxin (PT) were measured by ELISA in sera of 30 randomly chosen infants per group.</description>
          <population>Randomly chosen 30 participants in each group. Four in Comparison group 2 were excluded from analyses due to classification error.</population>
          <units>U/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-TT (U/ml) cord sera</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" lower_limit="2.94" upper_limit="10.62"/>
                    <measurement group_id="O2" value="3.92" lower_limit="1.98" upper_limit="7.58"/>
                    <measurement group_id="O3" value="4.37" lower_limit="1.01" upper_limit="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT (U/ml) at 7 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" lower_limit="3.18" upper_limit="6.97"/>
                    <measurement group_id="O2" value="5.16" lower_limit="3.16" upper_limit="8.32"/>
                    <measurement group_id="O3" value="4.03" lower_limit="2.78" upper_limit="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT (U/ml) at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0.36" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.73" upper_limit="1.17"/>
                    <measurement group_id="O3" value="0.53" lower_limit="0.37" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT (U/ml) at 13 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.31" upper_limit="0.56"/>
                    <measurement group_id="O2" value="5.15" lower_limit="2.85" upper_limit="12.01"/>
                    <measurement group_id="O3" value="NA">No blood samples collected at 13 months</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-DT (U/ml) cord sera</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.29" lower_limit="6.20" upper_limit="14.13"/>
                    <measurement group_id="O2" value="8.63" lower_limit="4.39" upper_limit="16.65"/>
                    <measurement group_id="O3" value="11.84" lower_limit="6.14" upper_limit="15.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-DT (U/ml) at 7 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.10" lower_limit="42.25" upper_limit="96.58"/>
                    <measurement group_id="O2" value="74.56" lower_limit="34.93" upper_limit="152.93"/>
                    <measurement group_id="O3" value="55.79" lower_limit="41.18" upper_limit="97.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-DT (U/ml) at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" lower_limit="5.62" upper_limit="13.24"/>
                    <measurement group_id="O2" value="10.07" lower_limit="4.95" upper_limit="18.78"/>
                    <measurement group_id="O3" value="9.10" lower_limit="5.60" upper_limit="15.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-DT (U/ml) at 13 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.93" lower_limit="6.06" upper_limit="11.19"/>
                    <measurement group_id="O2" value="8.66" lower_limit="4.33" upper_limit="15.42"/>
                    <measurement group_id="O3" value="NA">No blood samples collected at 13 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT (U/ml) cord sera</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.58" lower_limit="18.04" upper_limit="38.86"/>
                    <measurement group_id="O2" value="33.71" lower_limit="22.62" upper_limit="54.55"/>
                    <measurement group_id="O3" value="25.30" lower_limit="18.36" upper_limit="39.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT (U/ml) at 7 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.72" lower_limit="125.36" upper_limit="522.88"/>
                    <measurement group_id="O2" value="311.91" lower_limit="166.06" upper_limit="467.77"/>
                    <measurement group_id="O3" value="283.67" lower_limit="156.11" upper_limit="554.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT (U/ml) at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.86" lower_limit="20.38" upper_limit="77.06"/>
                    <measurement group_id="O2" value="41.03" lower_limit="19.86" upper_limit="73.04"/>
                    <measurement group_id="O3" value="42.94" lower_limit="28.31" upper_limit="71.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT (U/ml) at 13 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.86" lower_limit="14.89" upper_limit="51.21"/>
                    <measurement group_id="O2" value="33.52" lower_limit="14.51" upper_limit="70.22"/>
                    <measurement group_id="O3" value="NA">No blood samples collected at 13 months</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Responses to Hib CP</title>
        <description>IgG anti-Hib CP was measured by ELISA in sera of 30 randomly chosen infants per group</description>
        <time_frame>Cord sera and infant sera at 7, 12, and 13 months</time_frame>
        <population>Randomly chosen 30 participants in each group. Four in Comparison group 2 were excluded from analyses due to classification error.</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-rEPA Plus DTP</title>
            <description>Vi-rEPA plus DTP at 2, 4, 6 and Vi-rEPA at 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>Hib-TT Plus DTP</title>
            <description>Hib-TT plus DTP at 2,4,6 and Hib-TT at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>DTP Vaccines</title>
            <description>DTP at 2, 4, and 6 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Responses to Hib CP</title>
          <description>IgG anti-Hib CP was measured by ELISA in sera of 30 randomly chosen infants per group</description>
          <population>Randomly chosen 30 participants in each group. Four in Comparison group 2 were excluded from analyses due to classification error.</population>
          <units>mcg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Hib CP (mcg/ml) cord sera</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="0.99" upper_limit="3.95"/>
                    <measurement group_id="O2" value="1.33" lower_limit="0.75" upper_limit="3.18"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0.87" upper_limit="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hib CP (mcg/ml) at 7 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.11" upper_limit="0.53"/>
                    <measurement group_id="O2" value="8.35" lower_limit="2.95" upper_limit="29.65"/>
                    <measurement group_id="O3" value="0.33" lower_limit="0.20" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hib CP (mcg/ml) at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.09" upper_limit="1.23"/>
                    <measurement group_id="O2" value="1.79" lower_limit="0.98" upper_limit="3.21"/>
                    <measurement group_id="O3" value="0.37" lower_limit="0.20" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hib CP (mcg/ml) at 13 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.09" upper_limit="1.04"/>
                    <measurement group_id="O2" value="24.53" lower_limit="10.23" upper_limit="68.26"/>
                    <measurement group_id="O3" value="NA">No blood samples were collected at 13 months</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2, 4, 6 and 12 months</time_frame>
      <desc>Vaccinees were visited by health care workers at 6 hours, one and two days after each injection for measurements of temperature, inspection of injection site and record other systemic reactions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vi-rEPA Plus DTP</title>
          <description>Vi-rEPA plus DTP at 2, 4, 6 and Vi-rEPA at 12 months of age</description>
        </group>
        <group group_id="E2">
          <title>Hib-TT Plus DTP</title>
          <description>Hib-TT plus DTP at 2,4,6 and Hib-TT at 12 months of age</description>
        </group>
        <group group_id="E3">
          <title>DTP Vaccines</title>
          <description>DTP at 2, 4, and 6 months of age</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>A 5 month old injected 1 X with Vi-rEPA died of septicemia post surgery for &quot;nonfunctioning&quot; kidneys. A 4 month old died of pneumonia after 2nd injection of Hib-TT. Deaths were unrelated to study, noted only because they affect the participant flow.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Feng-Ying (Kimi) Lin, MD, MPH</name_or_title>
      <organization>PDMI, NICHD, NIH</organization>
      <phone>301-496-0295</phone>
      <email>link@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

